[en] The antimycotic activity of a new parenteral solution containing miconazole was compared with that of a marketed solution (Daktarin IV solution). This solution has been withdrawn from the Belgian market, probably because of toxic effects related to the presence of polyoxyl 35 castor oil. We propose a new formulation containing miconazole (10 mg/mL) (like the marketed solution), in combination with hydroxypropyl-beta-cyclodextrin and lactic acid. The MICs of these two solutions were determined by a broth microdilution method (based on NCCLS guidelines) for 67 yeasts and 50 filamentous fungi isolates. This study shows that the MICs obtained with these two solutions are not significantly different.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Piel, Géraldine ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique et magistrale
Sawyer R., Brogden R.N., Pinder R.M., Speight T.M., Avery G.S. (1975) Miconazole, a review of its antifungicidal activity and therapeutic efficacy. Drugs 9:406-423.
Kauffman A., Carver P. (1997) Use of azoles for systemic anti-fungal therapy. Advances in Pharmacology 39:147-189.
Brewster M.E., Estes K.S., Bodor N. (1989) Development of a non-surfactant formulation for alfaxalone through the use of chemically modified cyclodextrins. Journal of Parenteral Science and Technology 43:262-265.
Hopkins C.S. (1988) Adverse reaction to a cremophor containing preparation of intravenous vitamin. Intensive Therapeutic Clinical Monitoring 9:254-255.
Howrie D.L., Ptachcinski R.J., Griffith B.P., Hadersty R.J., Venkataramanan R. (1984) Anaphylactoid reactions associated with parenteral cyclosporine use: Possible role of cremophor EL. Drug Intelligence and Clinical Pharmacy 19:425-427.
Reynolds D.J., Aronson J.K. (1992) Selected side effects Part 8. Anaphylactoid reaction to intravenous vitamin K. Prescribers' Journal 32:167-170.
Cormican M.G., Pfaller M.A. (1996) Standardization of anti-fungal susceptibility testing. Journal of Antimicrobial Chemotherapy 38:561-578.
Pfaller M.A., Marco F., Messer S.A., Jones R.N. (1998) In vitro activity of two Echinocandin derivatives, LY3033366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagnostic Microbiology and Infectious Disease 30:251-255.
Piel G., Evrard B., Delattre L. (1997) Complexes à multi-composants de miconazole avec différents acides et cyclodextrines. Journal de Pharmacie de Belgique 52:124.
Piel G., Evrard B., Fillet M., Llabres G., Delattre L. (1998) Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins. International Journal of Pharmaceutics 169:15-22.
Brewster M.E., Estes K.S., Bodor N. (1990) An intravenous toxicity study of hydroxypropyl-β-cyclodextrin, a useful drug solubilizer, in rats and in monkeys. International Journal of Pharmaceutics 59:231-243.
Fromming K.H., Szejtli J. Cyclodextrins in Pharmacy, (Davies, J.E.O., Ed.). Kluwer Academic Publishers, Dordrecht.; 1994.
Yoshida A. (1988) Pharmaceutical evaluation of hydroxyalkylethers of β-cyclodextrin. International Journal of Pharmaceutics 46:217-222.
Piel G., Evrard B., Van Hees T., Delattre L. (1999) Comparison of the IV pharmacokinetics in sheep of miconazole-HP-βCD and SBE7-βCD solutions and a micellar solution. International Journal of Pharmaceutics 180:41-45.
1997.
(1998) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi: Proposed Standard M38-P. NCCLS., National Committee for Clinical Laboratory Standards. Wayne, PA.; .
Makimura K., Sudo T., Kudo M., Uchida K., Yamaguchi H. (1998) Development of reference procedures for broth microdilution antifungal susceptibility testing of yeasts with standardized endpoint determination. Microbiological Immunology 42:55-59.
Davey K.G., Holmes A.D., Johnson E.M., Szekely A., Warnock D.W. (1998) Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans. Journal of Clinical Microbiology 36:926-930.
Espinel-Ingroff A., Dawson K., Pfaller M., Anaissies E., Breslin B., Dixon D. (1995) Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrobial Agents and Chemotherapy 39:314-319.
Manavathu E.K., Alangaden G.J., Terner S.A. (1996) A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus. Canadian Journal of Microbiology 42:960-964.
Sutton D.A., Fothergill A.W., Rinaldi M.G. Clinically Significant Fungi, Williams and Wilkins, Baltimore, MD.; 1998.
